2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 480

Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 505

Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 373

Compared to Non-Users, Current Glucocorticoids Users Have Less Prevalent Fractures at the Same Bone Mass: Results of a Large Cross-Sectional Study

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 311

Comparison Between Intra Articular Ozone and Placebo in the Treatment of Knee Osteoarthritis: A Multicentric, Comparative, Randomized and Double-Blinded Clinical Trial

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 349

Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 192

Comparison of Bone Scan with Xiralite (FOI) in Patients with Rheumatoid Arthritis and Psoriatic Arthritis

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 548

Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 667

Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 748

Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 660

Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 438

Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 736

Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 30

Complications of Inflammatory Arthritis in First Nations and Non-First Nations Populations of Alberta, Canada

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 447

Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 176

Considerable Discrepancy Between Patient’s Assessment and Ultrasonography Assessment on the Most Affected Joint in Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].